Alex Fotopoulos
Hoofd Techniek/Wetenschap/O&O bij PASSAGE BIO, INC.
Vermogen: 89 710 $ op 31-05-2024
Profiel
Alex Fotopoulos is currently the Chief Technical Officer at Passage Bio, Inc. He previously worked as the Senior Director-Global Manufacturing Engineering at Biogen, Inc. from 1994 to 2011, Vice President-Technical Operations at Momenta Pharmaceuticals, Inc. from 2011 to 2016, Senior Vice President & Head-Technical Operations at Dimension Therapeutics, Inc. in 2016-2017, and Senior Vice President-Technical Operations at Ultragenyx Pharmaceutical, Inc. from 2017 to 2019.
Fotopoulos received a graduate degree from Tufts University in 1997 and an MBA from F.W.
Olin Graduate School of Business in 1998.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
PASSAGE BIO, INC.
0.13% | 18-03-2024 | 78 693 ( 0.13% ) | 89 710 $ | 31-05-2024 |
Actieve functies van Alex Fotopoulos
| Bedrijven | Functie | Begin |
|---|---|---|
| PASSAGE BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2019 |
Eerdere bekende functies van Alex Fotopoulos
| Bedrijven | Functie | Einde |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2019 |
| DIMENSION THERAPEUTICS INC | Hoofd Techniek/Wetenschap/O&O | 01-11-2017 |
| MOMENTA PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-05-2016 |
| BIOGEN INC. | Corporate Officer/Principal | 01-01-2011 |
Opleiding van Alex Fotopoulos
| Tufts University | Graduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
